AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1642487 — intervention group
Group type: COMPARATOR
Intervention: Model B of discharge planning rounds
Number of subjects: 0
Study 6143579 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipotiazine
Number of subjects: 90
Study 6143579 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 90
Study 6143579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 31262924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblate-covered everolimus
Number of subjects: 79
Study 31262924 — intervention group
Group type: COMPARATOR
Intervention: Non-oblate everolimus
Number of subjects: 79
Study 31262924 — intervention group
Group type: COMPARATOR
Intervention: Non-oblate everolimus followed by oblate-covered everolimus
Number of subjects: 79
Study 29253847 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine ER 120 mg
Number of subjects: 373
Study 29253847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 26880679 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic display
Number of subjects: 180
Study 26880679 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic display combined with music
Number of subjects: 180
Study 26880679 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard intervention)
Number of subjects: 180
Study 25514079 — intervention group
Group type: EXPERIMENTAL
Intervention: NuSmile® crowns
Number of subjects: 36
Study 25514079 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinder Krowns® crowns
Number of subjects: 36
Study 25514079 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental satisfaction
Number of subjects: 36
Study 25514079 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary maxillary first molar crowns
Number of subjects: 36
Study 25514079 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary mandibular second molar crowns
Number of subjects: 36
Study 22110019 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline galectin-3 levels
Number of subjects: 100
Study 22110019 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline galectin-3 above the median
Number of subjects: 100
Study 22110019 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 quartile relationship with HF risk
Number of subjects: 100
Study 22110019 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP added to the model
Number of subjects: 100
Study 19224305 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 30
Study 19224305 — intervention group
Group type: EXPERIMENTAL
Intervention: Obturator nerve block
Number of subjects: 30
Study 19224305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham block)
Number of subjects: 30
Study 19224305 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Femoral, Obturator, Placebo)
Number of subjects: 30
Study 17465658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with 35% hydrogen peroxide
Number of subjects: 48
Study 17465658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with 35% hydrogen peroxide + UltraEZ desensitizer
Number of subjects: 48
Study 17465658 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraEZ desensitizer alone
Number of subjects: 48
Study 17465658 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bleaching or desensitizer)
Number of subjects: 48
Study 15121021 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg iv ibandronate injections
Number of subjects: 2862
Study 15121021 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg iv ibandronate injections
Number of subjects: 2862
Study 15121021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2862
Study 11298697 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme
Number of subjects: 107
Study 11298697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational programme)
Number of subjects: 107
Study 9461704 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with monitoring of myoglobin concentration, CPK, and CK-MB activity.
Number of subjects: 50
Study 9461704 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of myoglobin concentration, CPK, and CK-MB activity at 3 hours post-thrombolytic treatment.
Number of subjects: 50
Study 9461704 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of total elevations of the ST segment 70% or more in electrocardiographic recording performed 3 hours after thrombolytic treatment.
Number of subjects: 50
Study 9461704 — intervention group
Group type: COMPARATOR
Intervention: Reduction of total elevations of the ST segment less than 30%.
Number of subjects: 50
Study 7948319 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 3300425 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% lidocaine carbonate
Number of subjects: 50
Study 3300425 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine hydrochloride
Number of subjects: 50
Study 28620791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 358
Study 28620791 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 358
Study 27370230 — intervention group
Group type: COMPARATOR
Intervention: Metformin with placebo
Number of subjects: 0
Study 27370230 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin with placebo
Number of subjects: 0
Study 27370230 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin with atorvastatin
Number of subjects: 0
Study 27370230 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 0
Study 25687344 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 387
Study 25687344 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 387
Study 23608625 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotene OralBalance® gel
Number of subjects: 41
Study 23608625 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 41
Study 19931408 — intervention group
Group type: EXPERIMENTAL
Intervention: human insulin B‐chain in incomplete Freund's adjuvant (IFA)
Number of subjects: 12
Study 19931408 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 18539460 — intervention group
Group type: COMPARATOR
Intervention: Eyes closed with no instructions (EC‐NI)
Number of subjects: 10
Study 18539460 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes open with instructions to gaze at a stationary black dot (EO‐WI)
Number of subjects: 10
Study 18539460 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes closed with instructions to imagine looking at the same target (EC‐WI)
Number of subjects: 10
Study 16500657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 873
Study 16500657 — intervention group
Group type: COMPARATOR
Intervention: Combination of Sulphadoxine-pyrimethamine and Artesunate (SP+AS)
Number of subjects: 873
Study 14645311 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 to 20 mg/d) with prophylactic benztropine (1 to 4 mg/d)
Number of subjects: 309
Study 14645311 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5 to 20 mg/d)
Number of subjects: 309
Study 10946101 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic peak torque in healthy subjects
Number of subjects: 36
Study 10946101 — intervention group
Group type: EXPERIMENTAL
Intervention: Average power in healthy subjects
Number of subjects: 36
Study 10946101 — intervention group
Group type: EXPERIMENTAL
Intervention: Total work in healthy subjects
Number of subjects: 36
Study 10946101 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric peak torque extension in healthy subjects
Number of subjects: 36
Study 10946101 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic peak torque in patients
Number of subjects: 36
Study 10946101 — intervention group
Group type: EXPERIMENTAL
Intervention: Average power in patients
Number of subjects: 36
Study 10946101 — intervention group
Group type: EXPERIMENTAL
Intervention: Total work in patients
Number of subjects: 36
Study 10946101 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric peak torque extension in patients
Number of subjects: 36
Study 9057170 — intervention group
Group type: COMPARATOR
Intervention: Control (blood transfusion history)
Number of subjects: 656
Study 9057170 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases (blood transfusion history)
Number of subjects: 656
Study 8103365 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal rectopexy with absorbable mesh made of polyglycolic acid (n = 17)
Number of subjects: 47
Study 8103365 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal rectopexy with absorbable mesh made of polyglactine 910 (n = 30)
Number of subjects: 47
Study 3089683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovral (50 micrograms ethinyloestradiol, EE2 and 500 micrograms levonorgestrel, LNG)
Number of subjects: 0
Study 3089683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordette (30 micrograms EE2 and 150 micrograms LNG)
Number of subjects: 0
Study 3089683 — intervention group
Group type: EXPERIMENTAL
Intervention: Norminest (35 micrograms EE2 and 500 micrograms norethisterone, NOR)
Number of subjects: 0
Study 30296537 — intervention group
Group type: EXPERIMENTAL
Intervention: Local excision margin (EM) >2 cm
Number of subjects: 0
Study 30296537 — intervention group
Group type: COMPARATOR
Intervention: Local destruction method
Number of subjects: 0
Study 30296537 — intervention group
Group type: EXPERIMENTAL
Intervention: EM >2 cm in patients <60 years of age
Number of subjects: 0
Study 30296537 — intervention group
Group type: EXPERIMENTAL
Intervention: EM >2 cm in patients with smaller tumor diameters (T1 and T2)
Number of subjects: 0
Study 30296537 — intervention group
Group type: EXPERIMENTAL
Intervention: EM >2 cm in patients who underwent adjuvant radiotherapy
Number of subjects: 0
Study 30296537 — intervention group
Group type: COMPARATOR
Intervention: Different EMs in patients ≥75 years of age or stage III tumors
Number of subjects: 0
Study 31109198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 400 or 800 mg, once daily for 3 consecutive days
Number of subjects: 0
Study 31109198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27455856 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Latino Black MSM
Number of subjects: 39301
Study 27455856 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreign birth (compared to US birth) for Black MSM
Number of subjects: 39301
Study 27455856 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreign birth (compared to US birth) for White MSM
Number of subjects: 39301
Study 27455856 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural residence for Black MSM
Number of subjects: 39301
Study 27455856 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural residence for Latino MSM
Number of subjects: 39301
Study 27455856 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural residence for White MSM
Number of subjects: 39301
Study 25907999 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0015% Tafluprost ophthalmic solution
Number of subjects: 246
Study 25907999 — intervention group
Group type: COMPARATOR
Intervention: 0.005% Latanoprost ophthalmic solution
Number of subjects: 246
Study 23474911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 91
Study 21831448 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive creatine 4 g daily for 8 weeks
Number of subjects: 5
Study 21831448 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (10 female adolescents)
Number of subjects: 5
Study 19487931 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/computed tomography of the thorax
Number of subjects: 10
Study 19487931 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 10
Study 17260705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional and non-nutritional interventions
Number of subjects: 0
Study 15537557 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg/day
Number of subjects: 22
Study 15537557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11262678 — intervention group
Group type: EXPERIMENTAL
Intervention: Post administration of the VCM1 questionnaire
Number of subjects: 188
Study 11262678 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration of the VCM1 questionnaire
Number of subjects: 188
Study 9557911 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 4.0 mg.kg(‐1) IV given 90 secs prior to tracheal intubation
Number of subjects: 0
Study 9557911 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 2.0 mg.kg(‐1) IV given 60 secs prior to eye bandaging and tracheal extubation
Number of subjects: 0
Study 9557911 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 1.0 ml. 10kg(‐1) prior to tracheal intubation
Number of subjects: 0
Study 9557911 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.5 ml. 10kg(‐1) prior to eye bandaging and tracheal extubation
Number of subjects: 0
Study 7741667 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical Chinese needle acupuncture for 5 weeks
Number of subjects: 20
Study 7741667 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure (mock electrical stimulation)
Number of subjects: 20
Study 2758870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g (i.m.) every 24 h
Number of subjects: 0
Study 2758870 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 1 g (i.m.) every 12 h
Number of subjects: 0
Study 7769502 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril hydrochloride, once a day for 8 weeks, with optional titration to a higher dose after 4 weeks based on DBP response.
Number of subjects: 135
Study 7769502 — intervention group
Group type: COMPARATOR
Intervention: Placebo, once a day for 8 weeks.
Number of subjects: 135
Study 7769502 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril hydrochloride (low dose), once a day for 8 weeks.
Number of subjects: 135
Study 581116 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized oestradiol (1, 2 or 4 mg)
Number of subjects: 10
Study 31820515 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentholated popsicle
Number of subjects: 40
Study 31820515 — intervention group
Group type: COMPARATOR
Intervention: Absolute fasting
Number of subjects: 40
Study 31044733 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy liquid used during the procedure
Number of subjects: 49
Study 31044733 — intervention group
Group type: COMPARATOR
Intervention: No heavy liquid used during the procedure
Number of subjects: 49
Study 28328303 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 sessions of cell phone-delivered smoking cessation treatment
Number of subjects: 474
Study 28328303 — intervention group
Group type: COMPARATOR
Intervention: Usual care (cessation advice and self-help materials)
Number of subjects: 474
Study 24852505 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment (specific, individualized postural and movement retraining, stretching, and functional weight‐bearing, strengthening exercises)
Number of subjects: 41
Study 24852505 — intervention group
Group type: COMPARATOR
Intervention: Local quadriceps strengthening, quadriceps stretching, and taping
Number of subjects: 41
Study 23431266 — intervention group
Group type: EXPERIMENTAL
Intervention: HSL inhibitor treatment
Number of subjects: 2
Study 23431266 — intervention group
Group type: EXPERIMENTAL
Intervention: HSL gene silencing in human adipocytes
Number of subjects: 2
Study 23431266 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic inhibition of lipolysis
Number of subjects: 2
Study 23431266 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunted lipolytic capacity in HSL haploinsufficient mice
Number of subjects: 2
Study 21301698 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs' usual assessment
Number of subjects: 29
Study 21301698 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifescripts tool
Number of subjects: 29
Study 21301698 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps per day (cut-off of 7500 steps/day)
Number of subjects: 29
Study 21301698 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual assessment)
Number of subjects: 29
Study 19566639 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education program (12 months duration, <30 min monthly interviews, biweekly telephone calls)
Number of subjects: 75
Study 19566639 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education program
Number of subjects: 75
Study 19566639 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice (control group)
Number of subjects: 75
Study 17415766 — intervention group
Group type: EXPERIMENTAL
Intervention: Targobone (bovine collagen and teicoplanin)
Number of subjects: 21
Study 17415766 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone grafts
Number of subjects: 21
Study 15292108 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-carnitine (2 g/d) + acetyl-L-carnitine (1 g/d)
Number of subjects: 239
Study 15292108 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine/acetyl-L-carnitine + 1 x 30-mg cinnoxicam suppository every 4 days
Number of subjects: 239
Study 15292108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 12008655 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody therapy with autologous peripheral blood stem cell transplantation
Number of subjects: 0
Study 12008655 — intervention group
Group type: COMPARATOR
Intervention: Monoclonal antibodies
Number of subjects: 0
Study 9718250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg)
Number of subjects: 0
Study 9718250 — intervention group
Group type: EXPERIMENTAL
Intervention: Kappa-opioid receptor agonist (7.5 mg)
Number of subjects: 0
Study 9718250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7858067 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 7858067 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 2684451 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of lignocaine
Number of subjects: 46
Study 1107508 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush only (modified Bass brushing technique)
Number of subjects: 24
Study 1107508 — intervention group
Group type: COMPARATOR
Intervention: Brush and floss
Number of subjects: 24
Study 1107508 — intervention group
Group type: COMPARATOR
Intervention: Brush and rubber tip
Number of subjects: 24
Study 1107508 — intervention group
Group type: COMPARATOR
Intervention: Brush, floss and rubber tip
Number of subjects: 24
Study 31343586 — intervention group
Group type: EXPERIMENTAL
Intervention: G1: inspiratory muscle training, active upper limb and lower limb exercise training, and early ambulation
Number of subjects: 40
Study 31343586 — intervention group
Group type: EXPERIMENTAL
Intervention: G2: same protocol as G1 without inspiratory muscle training
Number of subjects: 40
Study 31343586 — intervention group
Group type: EXPERIMENTAL
Intervention: G3: inspiratory muscle training alone
Number of subjects: 40
Study 31343586 — intervention group
Group type: COMPARATOR
Intervention: G4: control
Number of subjects: 40
Study 29150470 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 230
Study 29150470 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 230
Study 29150470 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP injection
Number of subjects: 230
Study 25421879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized sodium nitrite (AIR001) at a maximum tolerated dose (MTD) of 90 mg administered every 8 hours for 6 days
Number of subjects: 82
Study 25421879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized sodium nitrite (AIR001) at higher dosage levels (120 mg and 176 mg)
Number of subjects: 82
Study 25421879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized sodium nitrite (AIR001) under conditions of mild hypoxia and co-administration with sildenafil
Number of subjects: 82
Study 22990219 — intervention group
Group type: EXPERIMENTAL
Intervention: CO criterion for abstinence below 5 ppm (≤4 ppm)
Number of subjects: 261
Study 22990219 — intervention group
Group type: EXPERIMENTAL
Intervention: CO criterion for abstinence below 9 ppm
Number of subjects: 261
Study 22990219 — intervention group
Group type: EXPERIMENTAL
Intervention: High quit interest
Number of subjects: 261
Study 22990219 — intervention group
Group type: COMPARATOR
Intervention: Reinforcement of abstinence
Number of subjects: 261
Study 21496509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) for PTSD
Number of subjects: 150
Study 18553122 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative rofecoxib
Number of subjects: 79
Study 18553122 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-operative rofecoxib
Number of subjects: 79
Study 18553122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 18553122 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 79
Study 16087308 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon
Number of subjects: 18
Study 16087308 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam (as internal standard)
Number of subjects: 18
Study 14631882 — intervention group
Group type: EXPERIMENTAL
Intervention: Context structuring with 16.7% related words
Number of subjects: 38
Study 14631882 — intervention group
Group type: EXPERIMENTAL
Intervention: Context structuring with 33% related words
Number of subjects: 38
Study 14631882 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 38
Study 11800418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose atorvastatin (10 mg)
Number of subjects: 50
Study 11800418 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg)
Number of subjects: 50
Study 11800418 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (both doses)
Number of subjects: 50
Study 9674803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM)
Number of subjects: 6
Study 9674803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6